Adimab Announces Antibody Discovery C...

Adimab Announces Antibody Discovery Collaboration with Boehringer Ingelheim

Adimab, LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, today announced a multi-target partnership with Boehringer Ingelheim . Under the terms of the agreement, Adimab will use its proprietary platform to discover and optimize antibodies against targets chosen by BI, who will have the rights to develop and commercialize therapeutic programs resulting from the collaboration.

Start the conversation, or Read more at Customer Interaction Solutions.

Add your comments below

Characters left: 4000

Please note by submitting this form you acknowledge that you have read the Terms of Service and the comment you are posting is in compliance with such terms. Be polite. Inappropriate posts may be removed by the moderator. Send us your feedback.